Development of AVID100, a novel antibody-drug conjugate for the treatment of EGFR expressing solid tumors

被引：4
|
作者：
O'Connor-McCourt, M. [1 ]
Koropatnick, J. [2 ]
Maleki, S. [2 ]
Figueredo, R. [2 ]
Tikhomirov, I. [3 ]
Jaramillo, M. [4 ]
机构：
[1] Format Biol, R&D, Montreal, PQ, Canada
[2] Lawson Hlth Res Inst, Canc Res Program, London, ON, Canada
[3] Format Biol, R&D, Houston, TX USA
[4] Natl Res Council Canada, Human Hlth Therapeut, Montreal, PQ, Canada
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 69卷
关键词：
D O I：
10.1016/S0959-8049(16)33037-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
450
引用
收藏
页码：S147 / S147
页数：1
相关论文
共 50 条
  • [31] Antibody-drug conjugate [ADC] treatment of leukaemia
    Hassan, Hassan Tawhid
    LEUKEMIA RESEARCH, 2023, 131
  • [32] CNTN4 as a novel target for solid cancer with antibody-drug conjugate
    Cha, Mi Young
    Kim, Hyunuk
    Byun, Seungmin
    Ha, Youngeun
    Park, Kitae
    Yu, Hyunkyung
    Jeon, Bu-Nam
    Kim, Mira
    Moon, Soojung
    Park, Kyung Mi
    Park, Hansoo
    CANCER RESEARCH, 2024, 84 (06)
  • [33] Tisotumab vedotin Antibody-drug conjugate directed to tissue factor Tubulin polymerization inhibitor Treatment of solid tumors
    D'Alessandro, G.
    Barra, F.
    Boutros, A.
    Evangelisti, G.
    Desideri, L. Ferro
    Moioli, M.
    Ferrero, S.
    DRUGS OF THE FUTURE, 2020, 45 (10) : 717 - 724
  • [34] Is antibody-drug conjugate a rising star for clinical treatment of solid tumors? A systematic review and meta-analysis
    Zhang, Leyin
    Shen, Deyi
    Yu, Lulin
    Yan, Yici
    Wasan, Harpreet S.
    Yu, Jieru
    Zhang, Shuo
    Sun, Leitao
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 177
  • [35] Biomarkers for Antibody-Drug Conjugates in Solid Tumors
    Katrini, Jalissa
    Boldrini, Laura
    Santoro, Celeste
    Valenza, Carmine
    Trapani, Dario
    Curigliano, Giuseppe
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (04) : 436 - 446
  • [36] Preclinical development of YL202, a novel HER3-targeting antibody-drug conjugate (ADC) with novel DNA topoisomerase I inhibitor for treatment of solid tumors
    Xu, Jian
    Zong, Qing
    Zhu, Liang
    Liu, Qigang
    Stann, Sasha
    Cai, Jiaqiang
    CANCER RESEARCH, 2023, 83 (07)
  • [37] HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors
    Pegram, Mark D.
    Miles, David
    Tsui, C. Kimberly
    Zong, Yu
    CLINICAL CANCER RESEARCH, 2020, 26 (04) : 775 - 786
  • [38] Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
    Lambert, John M.
    Morris, Charles Q.
    ADVANCES IN THERAPY, 2017, 34 (05) : 1015 - 1035
  • [39] Preclinical development of NaPi2b-PL2202, a novel camptothecin- based antibody-drug conjugate targeting solid tumors expressing NaPi2b
    Horsley, Elizabeth
    Jabeen, Asma
    Veillard, Nicolas
    Havenith, Karin
    Janghra, Narinder
    Alves, Pedro
    Oblette, Cecile
    Kirby, Ian
    Hogg, Paul W.
    Zammarchi, Francesca
    de Haan, Lolke
    van Berkel, Patrick
    CANCER RESEARCH, 2024, 84 (06)
  • [40] ABT-414: An anti-EGFR antibody-drug conjugate as a potential therapeutic for the treatment of patients with squamous cell tumors
    Phillips, Andrew G.
    Boghaert, Erwin R.
    Vaidya, Kedar S.
    Ansell, Peter J.
    Shalinsky, David R.
    Zhang, Yumin
    Voorbach, Martin J.
    Mudd, Sarah
    Nolen, Kyle D.
    Humerickhouse, Rod A.
    Reilly, Edward B.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
12345